Azenosertib for Platinum-Resistant Ovarian Cancer
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Age
- 18 and older
- Sex
- Female
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 420 (estimated)
- Sponsor
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Industry
This trial is looking for women aged 18 or older with specific types of ovarian cancer that have not responded to platinum-based treatments. Participants will receive azenosertib or doctor’s choice of chemotherapy to see how well it works.
You may be able to join if
- I am a woman aged 18 or older
- I have high-grade serous ovarian, primary peritoneal, or fallopian tube cancer
- My cancer has measurable disease
- I have a performance status score of 0 or 1
- My tumor tests positive for cyclin E1 protein
- I have received prior treatments and am now platinum-resistant
- I have had prior treatment with bevacizumab, PARP inhibitors, or mirvetuximab as appropriate
- I have adequate blood and organ function
You may not be able to join if
- I have had another type of cancer in the last 2 years, except for some treated cancers
- I have platinum-refractory disease
- I have taken azenosertib or other specified inhibitors before
- I have active, uncontrolled infections
- I have serious medical conditions affecting my ability to participate
- I have had major recent surgeries or hospitalizations
- I am immunocompromised or HIV-positive on specific therapy
- I have active hepatitis B or C
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThis is a randomized, Phase 3 trial designed to evaluate the efficacy and safety of azenosertib compared to Investigator's choice of chemotherapy in subjects with platinum-resistant ovarian cancer whose tumors are positive for cyclin E1 protein expression.
Loading trial locations…